Whitefort Capital Discloses 8.1% Stake in Arbutus Biopharma

Key Facts

1Whitefort Capital reported an 8.1% beneficial ownership stake in Arbutus Biopharma (ABUS).

2The group acquired 15,794,261 common shares for approximately $41.8 million.

3The information was disclosed in an amended Schedule 13D filing detailing transactions over the past 60 days.

Whitefort Capital has disclosed an 8.1% beneficial ownership stake in Arbutus Biopharma (ABUS), marking a significant institutional move in the biotech sector. According to the latest regulatory filings, the group acquired 15,794,261 common shares for a total consideration of approximately $41.8 million. The details were revealed in an amended Schedule 13D filing, which outlines transaction activities carried out over the past 60 days. This accumulation of shares signals strong institutional confidence in Arbutus's valuation and its clinical pipeline. Market participants often view such substantial stakes as a bullish indicator for the company's corporate direction. The investment highlights a growing interest from specialized funds in targeted biotechnology assets.